Kala Pharmaceuticals (KALA) Investor Presentation - Slideshow

Innovation In Ophthalmology Corporate Overview September 2021 NOT FOR PROMOTIONAL USE Disclaimers and Notices 2 This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding Company's products, EYSUVIS®, for the short term (up to two weeks) relief of the signs and symptoms of dry eye disease, INVELTYS®, the first and only topical twice-daily ocular corticostero ...